Clinical Trial Update: Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant SBRT with intratumoural pembrolizumab followed by neoadjuvant chemotherapy in breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Breast Cancer, Breast Cancer Stage II | Phase 2 | Status: RECRUITING